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“Commercial Revolution” of Science: The Complex Reality and 






According to advocates and authors from different disciplines interested in 
biomedicine, biomedical research in genetics and genomics has the potential to 
transform medicine, the economy, society, and humanity as a whole. Believing in this 
potential, biomedical scientists produce knowledge and participate in the decisions 
concerning the orientation of this research and its applications. Through a qualitative 
analysis of scientists’ practice-related discourse, we identified three main sources of 
complexity in their involvement in the “commercial revolution” of science. First, 
scientists insist on the existence of different types of university-industry relationships. 
Second, they urge that the multiple realities of genetic and genomic research be 
acknowledged. Third, they present themselves as individuals in a diverse scientific 
community, each with a unique position in this commercial revolution. This paper 
draws attention to these complexities because they must be considered when engaging 
in a study of genetics and genomics advances from a research ethics perspective. 
 
Introduction: Impact of genetic and genomic advances and scientists’ views 
 
Genomics is sometimes presented by its advocates as a new paradigm that is 
transforming biology, medicine, and pharmacology.1,2 The economy emerging from 
the “commercial revolution” of science3 is one in which genetics and genomics play 
an exceptional role, as studies demonstrate.4,5 Influencing popular imagination, a 
powerful vector of social changes, the media presents scientists as manipulating DNA, 
producing clones or hybrids, etc.6,7 In addition, much research addresses the 
involvement of genetic mechanisms in reproduction or in gene inactivation, 
stimulation, and replacement. According to visionary scientists and philosophers, this 
research opens the door for an eventual post-human future, for better8,9 or 
worse.10,11,12 
 
Biomedical scientists who produce knowledge in genetics and genomics play an 
important role in orienting these fields and their applications. A literature review 
identified the few empirical studies conducted by social scientists that have analysed 
the experiences, perspectives, views, and opinions of these scientists. These studies 
are presented below in a summary that groups them by topics investigated. 
 
Surveys of US scientists demonstrated that on the whole, they reject the idea of 
patenting specific DNA sequences,13 are in favour of gene therapy on somatic cells 
for medical purposes,14 and approve of general access to genetic tests, prenatal testing, 
and abortion in case of serious diseases.15 Other American studies identify concerns 
among scientists about the sources of normative research frameworks,16,17,18,19 and one 
UK study shows that many researchers do not follow ethical guidelines.20 In the US 
and Europe, public attention (at times considered beneficial or less beneficial), public 
ignorance, controversies based on misconceptions or lack of information are also 
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subjects of concern for scientists.21,22 In the US and the UK, public outreach has been 
perceived as a means of informing the general public and gaining public confidence23 
and improving general scientific culture,24 and as a moral responsibility for all 
scientists,25 even when it is not supported.26 A Quebec study presented reflections on 
social responsibilities and the limits of science,27 while a UK study has identified 
strategies that help in considering scientists’ moral responsibilities: a better use of the 
scientific method, clarification of their roles, public debate, peer reviews or ethical 
evaluations, respect for normative frameworks, and personal responsibilities.28 
Discourse analysis has identified rhetorical strategies used by UK researchers to 
improve their public image,29 to dissociate genetics and eugenics,30 and to maintain 
expertise-associated power.31 This research concluded that these strategies can 
mislead the public and prejudice the scientists themselves;32 they are never naïve or 
inconsequential.33 Finally, studies addressing university-industry collaborations and 
the transformation of the nature of scientific inquiry,34 along with their perceived 
sources and consequences,35 addressed sensitive topics like conflict of interest and 
data withholding36 because genetic researchers in the US and Canada often have to 
deal with these issues.37 
 
 
Table I: Main topics of empirical studies with genetic/genomic scientists 
 
DNA patenting, gene therapy, genetic testing 
Normative frameworks and their sources 
Public attention 
Public outreach 




Because of biomedical scientists’ importance as knowledge producers in a field that 
may have significant impacts on our society and even humanity, we believe it is 
necessary to take into account their views on their actions and their impacts. Based on 
a literature review of empirical research, we identified different topics investigated 
with this population: DNA patenting, gene therapy, genetic testing; normative 
frameworks and their sources; public attention; public outreach; social and moral 
responsibilities; rhetorical strategies; university-industry collaborations. We 
discovered that no study concentrated on biomedical scientists’ experiences working 
in genetic or genomic research, as we can do based on our theoretical approach. Even 
when the topic of university-industry relationship has been investigated in other 
studies, it did not give the voice to scientists and allow them the opportunity to 
present their views on their practices and the changes occurring in science. 
 
This paper draws attention to science’s “commercial revolution” and how it is 
experienced by genetic and genomic scientists. The “commercial revolution” of 
science is presented in the literature as the transformation of science and universities, 
both of which are taking a commercial or entrepreneurial turn. Different models 
presented later in this paper have been developed to explain this “commercial 
revolution” of science: “mode 2 knowledge production”, when knowledge is oriented 
toward applications; “triple helix”, where universities, industry, and the State are 
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inextricably intertwined in a knowledge-based society; “academic capitalism” or; 
“enterprise universities.” 
 
This “commercial revolution” of science is the object of the central discussion of the 
paper because it has emerged as a major subject of concern for the scientists who 
participated in our study and who themselves identified three points of complexity to 
explore, among others that could have been identified:38 1) the different relationships 
experienced between universities and industries, 2) the multiple realities designated 
by the terms genetics and genomics research, and 3) the unique situation of every 
scientist, in a diverse scientific community, experiencing the “commercial revolution” 
of science. 
 
Methodology: Shedding light on scientists’ views 
 
Our study aims to shed light on biomedical scientists studying or using genetics and 
genomics views on their practice and its impacts. It recognises the importance of 
embedded “implicit normativity” in practices like research.39,40,41 These implicit 
normativities embedded in research represent scientists’ “aim for a good life”42 and 
can be identified in their descriptions of their own experiences, helping their authors 
give coherence to their actions.43 
 
 





Total number of scientists participating the study 32 
Number of scientists who wrote articles analysed in this study 12 
Articles 
 
Number of articles analysed 19 
Number of scientists approached 71 
Number of scientists interviewed 22 
Method 
Interviews 
Percentage of scientists approached who provided an interview 31% 
The methods used to collect scientists’ perspectives. Articles: nineteen articles in the mass media, 
written by twelve different scientists between December 1991 and May 2005 have been analysed. The 
“Bibliobranchée” database was used to identify articles written in French and English, addressing 
genetics, genomics, or research practices. Interviews: seventy-one e-mails were sent to researchers 
asking for their participation in a one hour semi-directed interview. Twenty-two tape-recorded 
interviews were conducted between January and December 2005. The qualitative analysis of both 
articles and interviews used the N’Vivo 2.0 program. 
 
 
Concerned by the possible implications of advances in genetics and genomics and 
taking into account scientists’ role as producers of knowledge, in this study we used 
descriptive methodologies to elucidate scientists’ views. Here we present data from 
semi-structured interviews with Quebec biomedical scientists and an analysis of press 
articles they published themselves (table II). Our interest lay primarily in their 
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practice and its impacts. However in the course of the study, the scientists themselves 
directed our attention to the “commercial revolution” of science and their role in it. As 
observed by other analyses (see empirical studies addressing university-industry 
collaborations and the transformation of the nature of scientific inquiry mentioned in 
the introduction), university-industry relationships are a significant preoccupation for 
scientists participating in our study. This paper presents various complexities 
scientists are facing which they specifically identified concerning this “commercial 
revolution” of science. 
 
 
Table III: Inclusion Criteria 
 
Working mainly in the Province of Quebec 
Working/Having previously worked as a scientific director 
Practising research in biomedical or related sciences 
Conducting research on a subject related to human health 
Studying genetics or genomics, or using tools from by these fields 
 
 
Table IV: Participants’ characteristics 
 
Sex   Experience   Region   Main Workplace  
Male 29  <15 yrs 6  Montreal 21  University 8 
Female 3  15-25 yrs 18  Quebec City 7  Hospital 4 
   >25 years 8  Sherbrooke 3  Research Center (Ind) 4 
Team Size      Chicoutimi 1  RC – University 3 
<10 people 9  Maternal Language      RC – Hospital 8 
10-25 people 12  French 23  Private sector links 20  Private Company 3 
>25 people 10  English 4     Government 2 
N/A 1  Other 5  Clinical Activities 8    
 
 
Quebec biomedical scientists studying genetics or genomics or using the tools offered 
by these fields (see table III for inclusion criteria) is our population of interest. To 
identify potential participants, we used lists of research financed by federally and 
provincially recognised granting agencies, lists of scientists affiliated with Quebec 
universities, hospitals, and governmental or universities research centres (RC), and 
private companies. Participants constitute a non-probabilistic sample of this 
population, thus ensuring that the selection of participants followed an internal 
diversification using the characteristics presented in table IV. Scientists’ research 
interests were also considered as a source of diversity; we identified those studying 
different biological processes and diseases, working in different disciplines, and using 
different approaches and techniques. 
 
Results: Concerns of genetics or genomics scientists participating in science’s 
“commercial revolution” 
 
The “commercial revolution” of science was identified in our study as being an 
important preoccupation for participant scientists, which is why the subject is central 
to our article. This concept has emerged from the discussion with our participants, and 
is used as a sensitising concept that allows empirical results to shed light on the 
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diversity and multiple meaning associated with it, in practice as well as in the 
literature.44 As a group, our participant scientists elucidated different types of 
relationships that exist between the academic and private research sectors; some of 
them insisted that these relationships can function very differently. They 
acknowledged that advances in genetics or genomics were playing an exceptional role 
in this “commercial revolution,” and some of them urged us to consider the multiple 
realities of this research. Some also demonstrated the diversity and distinctness of 
their different situations: they are individuals, in their institutions, living the 
“commercial revolution.” These scientists are extremely preoccupied with the three 
points of complexity that we will develop in this paper. 
 
i) The multiple types of relationships between academic and private research sectors 
 
Biomedical scientists participating in our study identified different factors they 
believe are pushing science toward a commercial logic (table V). Scientists consider 
the costs of research to be very high and ever increasing: 
 
‘Material, pharmaceutical and not just pharmaceutical like Fisher, 
WR and other suppliers… Everything cost so much!’ 
 
Scientists also believe that public and private research is under-financed by 
governments and that it is one factor that pushes academic scientists to associate with 
private companies. Some of them condemn this situation: 
 
‘I decry sometimes that the government does not fund universities 
that much, they push us more and more into getting money from 
private sources.’ 
 
Others believe in the necessity of transforming research results into applications, with 
some considering it is the scientist’s responsibility to communicate his or her 
discoveries. As one of our interviewees said: 
 
‘I think also it’s a responsibility to see whether what he discovers 
has any chance of being transferred to other laboratories and to, in 
my case, into hospital, transferred to industry in order to be made 
into new drug target, to be made into new diagnostic tools.’ 
 
Another factor identified by scientists pushing their research toward a commercial 
logic is the economic interest of new scientific advances like genomic research: 
 
‘The economic issues at stake around these discoveries are 
tremendous…Potential to create new categories of drugs is huge. 
Moreover, we expect innovative approaches of genomics to allow 
large scale savings…Genomics raises another economic interest: 
creation of new diagnostic tests…’ 
(translation) 
 
Finally, scientists are conscious that research does not evolve independently from its 
social context, and some of them mentioned the economic logic that governs our 
society in general, of which research is a part. This opinion, expressed by some 
participants, illustrates acceptance of economic control over science and scientific 
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activities. Other scientists, however, have expressed strong opposition to that 
economic control, which they deplore regrettably. Different views of research, which 




Table V: Factors identified by biomedical scientists as pushing science toward a 
commercial logic 
 
Costs associated with research 
+ 
Research under financing 
+ 




Science’s commercial revolution 
The participants’ description of the "commercial revolution" of science and factors participating to it. 
 
 
This is how the participants in our study describe the "commercial revolution" of 
science. What follows is a discussion on the multiple types of relationships between 
the academic and private sectors which were put forward by our participating 
scientists. We believe the multiple opinions and experiences presented illustrate the 
different meanings accorded by scientists to this transformation of science, multiple 
views being explained in part by the diversity and individuality of scientists (see 
section iii) below). Before presenting this discussion, we contextualise this 
“commercial revolution” of science by summarising four models describing the 
transformation of science. These illustrate the multiple interpretations that can result 
from these changes. 
 
Within the social sciences and humanities community of researchers and thinkers, it is 
undisputed that science and the knowledge it produces have been transformed in 
recent years; universities have evolved accordingly. Regarding economic 
considerations, many have observed that in the past decades - in the eighties in the US 
and the nineties in Canada - the universities have adopted an economic mission.45 
Some authors consider this evolution as the second revolution taking place in the 
universities; following the first revolution, in which research entered the universities, 
it is now the time for the “entrepreneurial revolution”46 or the “commercial 
revolution.”47 
 
Table VI: Models of the transformation of science and universities: some examples 
 
1) “Mode 2” knowledge production 
2) “Triple helix” model 
3) “Academic capitalism” theory 
4) “Enterprise universities” 
Four models of the transformation of science and universities under the “commercial revolution” 
identified in the social and humanity scientists’ and thinkers’ community. 
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The transformation of science and universities is a subject widely covered in literature 
and has been reviewed in an article presented by the Finnish sociologist Juha 
Tuunainen in which he identified four models of transformation48 (see table VI). 
These models differ in their view of this transformation. The first two models are 
enthusiastic about a dramatic global change in society, including universities, 
industry, and government. The third and fourth models emphasise moderate, 
diversified changes in universities, and their controversial effects. 
 
The first model is presented by the English Science Policy expert Michael Gibbons 
and his colleagues.49,50 It argues that research practices associated with “Mode 2” 
knowledge production, when knowledge is oriented toward applications, are replacing 
research practices associated with “Mode 1,” “traditional” scientific knowledge 
production. This situation is completely transforming universities, industry, and 
government, and the relationships between them. 
 
The second model observes a dramatic evolution of science, knowledge, and 
universities. It is the well-known “triple helix” model presented by the English 
professor of Management and Innovation, Henry Etzkowitz, and his colleagues.51 This 
model exposes a new configuration in the relationship between universities, industry, 
and the State, which are inextricably intertwined in a knowledge-based society. The 
triple helix model demonstrates the arrival of the “entrepreneurial paradigm” in 
academic science,52 the development of “entrepreneurial universities” and “quasi-
firms” research groups.53 According to this model, universities have become central 
actors in the innovation processes and in social transformation.54 For some authors, 
this model of university-industry-government relations appears in a common format 
as a worldwide phenomenon55 in various countries and transcends national 
boundaries.56 
 
The third model refers to the “academic capitalism” theory. Two American professors 
of Higher Education Administration, Sheila Slaughter and Larry Leslie, developed 
this theory to explain how universities present “market and market-like” behaviours,57 
and to explain the behaviours of actors like scientists and administrators.58 These 
authors look at how “academic capitalism” influences universities as organisations. 
 
Tuunainen’s fourth model, the concept of “enterprise universities,” is presented by the 
Australian professors Simon Maginson, who studies education, and Mark Considine, 
who studies public policy. After empirical research in Australian universities, these 
professors used this concept to designate the pattern they observed: namely, that since 
the mid-1980s, universities were becoming more and more like enterprises. These 
authors find the roots of this change in the history of the universities, and they present 
the thesis that different universities undergo the change differently. 
 
In the literature on the “commercial revolution” of science, many authors have stated 
that science has had practical aims throughout its history and that relationships 
between universities and industry are not new: there have been “important linkages 
between the history of university science and the corporate laboratories.”59 Some 
insist that throughout history, research goals have been alternatively fundamental and 
applied.60 Different societies have different needs and objectives that often influence 
the direction of research. Practical aims for scientific inquiries are found as early as 
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the 17th century, when discoveries were often fuelled by an effort to improve 
industries such as navigation or mining.61 The beginning of the academic 
“entrepreneurial revolution” in the United States can be traced to the 19th century, to 
the founding of the Massachusetts Institute of Technology (MIT).62 
 
Though relationships between universities and industry are not new, many observers 
believe that the last few decades have brought the commercial revolution of science to 
a new level.63,64 Analysts have attributed this revolution to different causes: 1) 
economic globalisation;65 2) reduction in government funding;66 3) new government 
priorities67 that see universities as central to innovation and to the knowledge-based 
economy;68 4) development of agreements encouraging university-industry 
relationships,69 financing of Industries-Liaison Offices70 and laws such as the Bayh-
Dole Act (1980) in the United Sates71 that promote technological transfer from public-
financed research to the private sector;72 5) universities’ own financial interests.73 
 
The four models of science and university transformation presented above are 
interesting ways of describing the transformations occurring in institutions and 
science in a global perspective. In the undisputed context of the “commercial 
revolution,” universities and industry do not evolve separately. Also, the links that 
relate the two research sectors are multiple; scientists in both sectors interact. Our 
study offers insight on how these transformations are experienced by participant 
biomedical scientists. First, some participant biomedical scientists observed that 
current scientific research in both contexts share characteristics that cannot be 
restricted to one research sector. Some examples: research is generally oriented 
toward priorities which focus on short- or long-term applicability; research costs 
money and must be financed somehow; information and results are retained to 
maintain a competitive edge in both the academic and industry setting; contribution is 
recognised in terms of money or publications. The scientists who expressed this idea 
recognise the hybrid nature of academic science and the explicit links between basic 
and applied research and between the academic and industry visions of research. 
However, other academic scientists do not recognise science’s hybrid nature and try 
by every means to pursue “pure science” in their university-based laboratory. This 
illustrates the multiple views or research put forward by different scientists. 
 
 
Table VII: Types of relationships between academic and private sectors of research as 
depicted by participant biomedical scientists in this study 
 
Contracts between scientists or organisations 
Collaborations between scientists or organisations 
Academic research financed by private funding 
Consultation and expertise exchange 
Commercialisation and patents 
Start-up, spin-off, incubation of companies in universities 
The transformations occurring within the “commercial revolution” of science and universities as 
experienced by biomedical scientists who participate in different types of relationships. 
 
 
Second, participant scientists described their experience of science’s “commercial 
revolution” in terms of different types of relationships (table VII). Some of them insist 
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that there are many types of relationships, each being unique in its possible 
consequences. This constitutes the first point of complexity this paper analyses. 
 
The subject of contractual relationships between scientists and organisations was 
addressed by our participants. They discussed many different types of contracts, 
which can be classified in the different categories:74 collaborations in which both the 
university and the industry are equal partners, contracts in which a private firm is the 
principal and the university provides services, and contracts in which a university is 
the principal and the firm provides services. 
 
Collaborations, in which both the university and the industry are equal partners, are 
one type of relationship existing between scientists or between organisations. 
Collaborations can take different forms, and include the sharing of results, products, 
techniques, specific expertise, etc. One interviewee explained that good contractual 
collaborations between university and industry were solidified in a spirit of 
partnership: 
 
‘If you have two groups of scientists, one in academia and one in the 
pharmaceutical industry working together to solve one problem, 
both with their strengths, both with their methods and techniques, 
that’s good. And you see that a lot…When you have equals and you 
have a clear objective, you try to find a solution to a scientific 
problem…that’s totally, totally fair.’ 
 
Speaking of contracts in which a firm is the principal and the university provides 
services in general, one participant believed contracts constituted a clear and fair type 
of relationship between an academic scientist and a private company: 
 
‘you have pure contractual work. So the industry asks you to do 
something. That’s also clean and clear: you can say yes or you can 
say no but you do a certain task for a certain amount of money, and 
then the results will totally belong to pharmaceutical industry. I 
think that’s also fair, because then you can decide whether you 
accept it or not.’ 
 
Another participant indicated that he found that contracts in which a firm is the 
principal and the scientist provides technical services and technological transfer of 
automated research protocols were leading to boring science: “Scientists don’t like 
that, because those are kind of boring science, generally.” This scientist does not 
consider that kind of contract exciting or likely to lead to new discoveries, which are 
the basis of his motivation. 
 
Academic research financed by private funding is another type of private-academic 
contractual relationship, in which a firm is the principal and the university provides 
services. This has been reported as “occurring more and more often” (translation). 
Some academic and government scientists have pointed out that finding financing 
from the private sector was not necessarily an easy task for them. 
 
Another issue associated with this type of relationship is that when financing an 
academic scientist, a company becomes a partner in his/her research. Many 
participants underlined that this presented the perverse effect of “giving research 
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efforts to companies” (translation) in situations where the research is co-financed by 
the public and the private sector. The interviewee did not provide any explanation to 
support his/her position, but this is an opinion shared by some academic scientists 
from our study as well as others.75 The gift of academic research efforts, given to 
companies, was considered particularly perverse when the financing company was not 
Canadian. This last idea is the opinion of the interviewee, and it was shared by some 
other academic scientists though not by the ones who proactively make collaborations 
with American companies, or by the Canadian government76 or Genome Canada, the 
principal funding agency for genomic research in Canada. 
 
Consultation and exchange of expertise are other kinds of contracts that link 
universities and firms. For example, some academic participants have reported work 
as consultants for the private sector, and some scientists from the private sector give 
information sessions or sit on academic committees. These exchanges of expertise 
tighten the links between the private and academic sectors of research. 
 
Academic scientists sometimes commercialise their inventions, products, or 
techniques. Genetic tests are a good example of a product that can be patented and 
commercialised by academic scientists and their institutions. This way of proceeding 
was valued by academic scientists with different perspectives, even those who do not 
want to orient their research toward applications, whether the university contracts a 
firm to provide commercialisation services or not: 
 
‘Patenting…we didn’t believe in it, this orientation, okay, but we are 
not fools either. We said to ourselves, if we find something, we’ll 
have our eyes open and be vigilant’ 
(translation) 
 
Academic scientists sometimes start companies based on the research results they 
have obtained in their academic laboratory. The academic scientist then adds the role 
of entrepreneur to his curricula of teaching and research. In some of these situations, 
universities or research centers also serve as incubators for the development of such 
companies. 
 
Appreciation of the different types of relationships between the private and the 
academic sectors of research leads to a more specific analysis of the situation. 
Conflicts of values may differ depending on the types of relationships. For example, 
values such disinterest (implying no financial attachments) or honesty in presentation 
of results are not equally threatened by the traditional aims of industry; some are in 
absolute contradiction while others can fit into a commercial vision of research. A 
conflict of interest is not of the same nature when a partnership links two scientists 
from both environments compared to when a scientist holds an academic position 
while chairing a private company. Circulation of information may not be affected 
equally by a patent on a genetic test and a contract between a big pharmaceutical 
company and an academic scientist identifying genes that alter individuals’ response 
to a drug. The strategies put in place to regulate these different types of relationships 
have to take into account the actual situations. 
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ii) Of genetics, genomics, and the multiple realities they designate 
 
Some participants believed that the focus on applications and profits was significant 
in the field of genetics: 
 
‘It is more or less evident that in genetics, in biology, today we aim 
to have concrete results, and we hope that these results will be of the 
kind that, after, we will be able to fund more projects’ 
(translation) 
 
The belief that the field of genetics is oriented toward applications is shared by 
analysts who have identified genetics as an exception in the “commercial revolution.” 
Specifically, physicist and public health policy expert David Blumenthal and his 
colleagues at Harvard University observed this phenomenon through their quantitative 
surveys of American academic scientists.77 When comparing genetics to other 
biomedical fields, the team found that there are more companies financing academic 
research in genetics and that the financing is more generous and extends over a longer 
period of time. Genetics scientists report more often that they have obtained licences 
or patents, or that they have started companies linked to their work. 
 
As stressed by participant scientists and analysts, the “commercial revolution” does 
not affect all research fields equally.78 Some scientists who participated in our study 
extended this observation to the multiple types of research comprised by the terms 
“genetic research” and “genomic research.” These multiple realities designated by the 
terms “genetics” and “genomics” constitute our second point of complexity.  
 
In identifying the population of scientists who participated in our study, we tried to 
acknowledge the multiple realities designated. That is why we used the expression 
“biomedical scientists studying genetics or genomics, or using the tools they offered.” 
First, we used the terms “genetics” and “genomics” because they sometimes designate 
two very different research fields, even if their actual differences and specificities are 
often blurred together by lay people as well as by experts (including our participants). 
Beyond their most basic definitions - study of genes and/ or genomes - these terms are 
not totally specific and not everyone agrees on their meaning. These words from a 
participant biomedical scientist illustrate this affirmation: 
 
‘…often genomics, many use it to refer to population genetics, but it 




Second, the labels “genetic” or “genomic” are attached to different kinds of research. 
Different disciplines are concerned and different approaches, techniques, tools, and 
methods are included. Supporting this assertion, some participants emphasise the idea 
that “genomics” is a very large term that includes genetics, proteomics, 
bioinformatics, population genetics, functional and regulatory genomics, etc. It is 
perceived as a mix of different approaches: cytogenetics, arrays, sequencing, 
genotyping, etc. One scientist complained that only one negative connotation is 
associated with the term by social scientists and ethicists when in fact it designates 
multiple realities: 
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‘for me, genomics is an all-encompassing term, and there is only one 




A third level of complexity is added when genetics or genomics are considered as 
research fields or tools that can be used to study a particular subject. Some scientists 
in our study embrace their practice with the aim of forwarding the field of genomics 
itself: for instance, they develop both techniques at the edge of scientific knowledge 
and statistical or informatics tools necessary to manage the data produced. Other 
scientists are interested in using genetic and genomic tools to generate knowledge on 
diseases like breast cancer: 
 
‘Genomics as such, it’s a research tool…In itself, it is not an end, 
it’s…it’s a mean to reach identification.’ 
(translation) 
 
Another layer of complexity develops when the research is applied to subjects like 
monogenic diseases, polygenic diseases, individual responses to drugs, gene 
modifications, mechanisms implicated in cloning, or population genetics, which 
represent activities very different from each other. 
 
The later development illustrates the multifaceted or generic nature of the terms 
“genomics” and “genetics”. This begs the question of what such all-embracing terms 
really mean for scientists and how effectively they use them. Are they only buzzwords 
used by scientists to fit strategically their research interest into funding agencies or 
companies orientation or to get social support, as denounced in the literature79 and 
implied by the following quotation of one of our participant scientist? 
 
‘…my scientific interest, which is sort of what drives me, is based on 
my research in [specific research field]…So I want to keep doing 
that. I don’t want to change’ 
 
Or do they designate new realities needing new terminologies and potentially leading 
to new scientific paradigms? Proponents of the two discourses fiercely defend their 
opinions, and the reality probably exists somewhere between these two extremes. 
 
To conclude and link this section with the key theme of our article, namely “the 
commercial revolution of science”, we want to stress that the potential impact of the 
results obtained and the forms of knowledge produced in different research situations 
are not comparable. In respect to commercialisation, the results do not hold the same 
degree of applicability; their potential markets and commercial interests are 
completely different. This illustrates that there are many different types of research 
and potential for commercialisation in one relatively small and well-defined research 
field. 
 
iii) Diversity of individual scientists in a scientific community 
 
Our study allowed us to appreciate the individuality of every participant scientist, and 
therefore the associated diversity of particular situations found in the research 
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practices of the scientific community. Scientists are the individuals who live the 
“commercial revolution,” and they present themselves as a diverse community. This 
constitutes another complexity to consider. 
 
The life contexts of scientists influence their research practices. For example, the 
culture of origin and of the region where they practise research may have a decisive 
influence on their vision of commercialisation or profit making. In the same way, the 
culture of their main workplace - university, research centre, hospital, private 
company - has to be considered. For example, a clinician and researcher working in a 
hospital and its research centre may have a different experience of the reality in which 
his or her research can be applied from the experience of a basic scientist who works 
in an environment centered on the advancement of knowledge. These elements of life 
context interact and influence the vision of specific scientists and their research 
practices. The scientific community shares some beliefs and views; however, the 
particular situations of individual scientists make them different from one another and 
bring diversity to the views presented by the community. This is why sometimes - and 
we saw it repeatedly during our study - the scientists’ vision does not precisely align 
with their employer’s vision. In such a situation, the scientists focused on their 
fundamental interest when employers pushed them toward development of 
applications: it creates conflicts of engagement. This assertion from one of our 
participants is an illustration of such a conflict of engagement: 
 
‘…my scientific interest, which is sort of what drives me, is based on 
my research in [specific research field]…So I want to keep doing 
that. I don’t want to change. And if somebody says, well you’ll have 
to be doing something that’s practical, I will try and say here’s what 
is practical in what I want to be doing.’ 
 
As identified in a study on the use of the term “basic research” by scientists,80,81 
intentions (curiosity, social benefits, etc.) partly delimit scientists’ vision of research 
and therefore, its possible applicability. However, in order to respond to employers’ 
demands or to secure funding, scientists may present their work with a different 
emphasis on its possible application. This is one situation in which scientists’ 
discourses may blur the distinction between basic and applied research, without 
changing their initial intention. This strategy, as expressed in the last quotation, may 
be used in order to preserve the scientist’s autonomy and to keep a distance from 
application. 
 
We can also add that many scientists accumulate professional attachments, which 
might be with clinicians and researchers appointed to a university, chairs of 
companies and university professors. These multiple roles may expose a scientist to 
different visions of research that may create tensions and lead to conflicts of values or 
interests. The numerous combinations of professional attachments lead to a diversity 
of personal situations that must be acutely understood. 
 
Different scientific disciplines have different cultures and potential for the application 
of research. Genetic and genomic research is often interdisciplinary and illustrates the 
diversity of expertise needed to embrace projects in new scientific advances: 
engineers and computer scientists meet physicists, biochemists, molecular biologists, 
etc. Objects of study chosen by scientists also vary in their potential for application. 
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For example, biomedical researchers focus their research on human health, which is 
itself a step toward the application of research. Other factors also contribute to 
scientists’ views of the “commercial revolution” that they are experiencing and their 
role in it. The context of their specific research team influences the sum of money 
they need to operate, for example, and their previous experience, along with other 
factors, influences the potential to obtain funding from different sources. 
 
Scientists who experience the “commercial revolution” of science and its impacts are 
individuals. One consequence of the revolution is the transformation of the scientist’s 
role. Expertise in more than one field is necessary to operate at a time when 
relationships between universities, industries and government are tighter. Riccardo 
Viale, an Italian researcher in public policy discusses the birth of a new type of 
scientist, “the entrepreneurial scientist”, who is able to “interface basic knowledge 
with the innovation goal”.82 Because of their diversity of backgrounds and 
experiences, not all scientists experience the evolution of their role to the same extent; 
some of them enthusiastically embrace this entrepreneurial role while others are 
reluctant to enter the “commercial revolution.” Comprised in their own life history, 
scientists’ views of research are influenced by different factors. How these factors 
influence scientists’ willingness to develop applications and how scientists experience 
the "commercial revolution" of science have implications for the way future research 
is carried out and therefore for the future of science itself. 
 
Discussion: studying the “commercial revolution” of science from a research 
ethics perspective 
 
Scientific advances in biomedicine that studies or uses genetics and genomics in the 
context of the “commercial revolution” of science constitute an inescapable subject of 
concern which is extensively discussed in the social science and humanities literature. 
Many authors have identified the controversial effects of the “commercial revolution” 
of science. Case studies have shed light on the different problems created by 
university and industry’s increasing and changing relationships—harassment of 
scientists, conflicts of interests, failures to protect human subjects, lawsuits over 
results publication, publication bias, diminished integrity and research productivity, 
diminished public confidence and free circulation of information, disputes over 
intellectual property, etc.83,84,85,86,87 Problems have even been associated more 
specifically with the practice of research in the field of genetics: one study confirmed 
that American genetics researchers, more than researchers in other fields, were 
retaining information (not publishing data, not discussing new results with colleagues, 
etc.) and that it affected their scientific activity in terms of productivity and 
exchanges. These cases are sometimes considered illustrations of what is called a 
“culture conflict”88 arising between academic research and private sector values. 
Different values are said to be specific academic ideals - openness, objectivity, 
academic freedom, scepticism, preservation and dissemination of knowledge, etc.89 
These values are transmitted from generation to generation during the scientists’ 
education, and we believe they constitute scientific norms, their adherence making the 
scientists members of the scientific community. Market-driven production, profit 
orientation, and utilitarianism are traditionally associated with industry.90 In practice, 
these norms are ideals and universities also have interests and work in a context that 
directs their knowledge production.91 However, we agree with authors who claim that 
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the clash of values in increasing or intertwined relationships could compromise 
traditional academic norms as well as industry’s mission.92 Related to conflicts of 
values, the issue of conflicts of interests (COI) has attracted a great deal of attention in 
the context of the “commercial revolution” of science. Authors have presented case 
studies (8), definitions and categorisations of the concept.93 Analysts, including 
governments, funding agencies, institutions, professional associations, and scientific 
journals, have presented strategies to respond to COIs.94 An academic team of social 
scientists has presented a code of conduct suggesting the disclosure of COIs, the 
implementation of nationwide standards and guidelines, hearing processes, 
certification, surtax on university-industry contracts, ombudsperson, etc.95 
 
These problems arising in the context of the “commercial revolution” of science raise 
various questions. How can universities protect their specific culture?96 How can we 
address conflicts created by the tension, conflicts which are sometimes considered 
creative?97 
 
We believe that current research ethics, which have been built and are still articulated 
around principles, norms and application rules aim to protect research subjects, are 
not well adapted to new knowledge development like genetics and genomics research 
in the context of the “commercial revolution” of science. Codes of conduct and 
guidelines constitute steps in the ethical conduct research, but they present limits 
when confronted to particular situations. As we demonstrated, the actual practice of 
research in the field of genetics and genomics and in the context of the “commercial 
revolution” of science presents a complexity that cannot be addressed by principles 
and rule applications. Starting from this observation, we plead for a broadening of 
research ethics that would be interested in practices, implicit normativities, and the 
views they imply. In our view, research ethics should provide the foundation to 
address the following questions. What is good research? What type of research should 
be valued? What kind of knowledge do we want to produce? With what aim? 
Moreover, the practice of research ethics should allocate considerable efforts to the 
formation, sensitisation and development of scientific integrity by the actors 




This article takes into account that, in practice, the “commercial revolution” of 
science is occurring in many different ways and that the actual situations of the 
scientists who live these transformations present multiple element of complexity. An 
important point of this article is to warn analysts not to over-generalise when they 
address issues emerging from this “commercial revolution”. Development of 
principles, norms, codes of ethics or guidelines to regulate relationships between 
university and industry constitute a step toward ethical conduct of research. However, 
when judging problematic situations or in applying general rules of regulation to 
specific cases, the complexity of concrete situations must always be considered. 
Through interviews with scientists and consideration of the literature, our article 
highlights some complexities to consider when studying genetics- and genomics-
related scientific advances in the context of science’s “commercial revolution” from a 
research ethics perspective. Specifically, we have addressed the following points: i) 
the multiplicity and uniqueness of university-industry relationships; ii) the multiple 
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realities of research designated by the terms “genetics” and “genomics;” iii) the 
individuality of each scientist and diversity of the scientific community facing the 
“commercial revolution.” 
 
Our discussion merely opens the door for the identification of other complexities and 
points to the pursuit of work and reflection on how universal principles and rules can 
be developed and applied to concrete situations. Development of dialogue between 
scientists from the social sciences and humanities and actors related to their object of 
study - such as biomedical scientists - is a necessary step toward a sophisticated and 




We thank the Groupe de recherche en bioéthique and Genetics and Society Project 
team members from the Université de Montreal for their support and comments. We 
also thank A. Saginur for linguistic corrections. A special thank to B.M. Knoppers and 
H. Doucet for their guidance and support. This study was supported by a doctorate 
grant from Fonds québécois de la recherche sur la nature et les technologies, a travel 
scholarship from the International Institute of Research in Ethics and Biomedicine 
and a grant from Genome Quebec. 
 
 
                                                 
1 A.E. Guttmacher and F.S. Collins. Genomic Medicine - a Primer. New England Journal of Medicine 
2002; 347(19): 1512-1520. 
2 A.E. Guttmacher and F.S. Collins. Welcome to the Genomic Era. New England Journal of Medicine 
2003; 349(10): 996-998. 
3 A. Schafer. Biomedical Conflicts of Interest: A Defence of the Sequestration Thesis-Learning from 
the Cases of Nancy Olivieri and David Healy. Journal of Medical Ethics 2004; 30, 1: 8-24. 
4 D. Blumenthal, N. Causino and E.G. Campbell. Academic-Industry Research Relationships in 
Genetics: A Field Apart. Nat. Genet. 1997; 16(1): 104-108. 
5 D. Blumenthal, E.G. Campbell, M. Gokhale, R. Yucel, B. Clarridge, S. Hilgartner and N.A. 
Holtzman. Data Withholding in Genetics and the Other Life Sciences: Prevalences and Predictors. 
Academic Medicine 2006; 81(2): 137–145. 
6 D. Nelkin. Molecular Metaphors: The Gene in Popular Discourse. Nature Review Genetics 2001; 
2(7): 555-559. 
7 D. Ducharme. 2003. Débat Sur La Génétique Humaine Au Québec: Représentations Et Imaginaires 
Sociaux. Montréal. Hurtubise HMH: 286. 
8 A. Woolfson. 2005. Genetics: The Future of Life College of Medecine, Heath Park Campus, Cardiff. 
Cardiff University. 
9 D. Kevles. 1992. Out of Eugenics: The Historical Politics of the Human Genome. In The Code of 
Codes. L. Hood and D. Kevles, eds. Harvard. Harvard University Press: 18. 
10 F. Fukuyama. 2002. Our Posthuman Future: Consequences of the Biotechnology Revolution. New 
York. Farrar, Straus and Giroux: 256. 
11 J. Habermas. 2003. The Future of Human Nature. Malden. Polity Press: 136. 
12 J. Derrida. 1990. The Aforementing So-Called Human Genome. In Negotiations: Interventions and 
Interviews, 1971-2001. E. Rottenberg, ed. Stanford. Stanford University Press: 199-214. 
13 I. Rabino. How Human Geneticists in Us View Commercialization of the Human Genome Project. 
Nature Genetics 2001; 29(1): 15-16. 
14 I. Rabino. Gene Therapy: Ethical Issues. Theorethical Medicine and Bioethics 2003; 24(1): 31-58. 
15 I. Rabino. Genetic Testing and Its Implications: Human Genetics Researchers Grapple with Ethical 
Issues. Science, Technology and Human Values 2003; 28(2): 365-402. 
16 I. Rabino. Ethical Debates in Genetic Engineering: U.S. Scientists' Attitudes on Patenting, Germ-
Line Research, Food Labeling, and Agri-Biotech Issues. Politics Life Sciences 1998; 17(2): 147-163. 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2006, Vol.2, No.3, pp.96-114 
 
_____________  112 
 
Genomics, Society and Policy, Vol.2 No.3 (2006) ISSN: 1746-5354 
                                                                                                                                            
17 I. Rabino. What U.S. Researchers Think of Regulations and Regulators: If Regulators Contain Their 
Political Excesses and Become More Effective, DNA Researchers Will Give Them Guarded Approval. 
Bio/technology 1996; 14(2): 147-150. 
18 I. Rabino. German Genetic Engineering Scientists and the German Public: Complementary 
Perceptions in a Changing European Context. Public Understanding of Science 1992; 3(4): 365-384. 
19 D.J. Mathews, A. Kalfoglou and K. Hudson. Geneticists' Views on Science Policy Formation and 
Public Outreach. American Journal of Medical Genetics 2005; 137(2): 161-169. 
20 N.J. Goulding, H.C. Waddell and L. Doyal. Adherence to Published Ethical Guidelines by the UK 
Genetics Research Community. Nature Genetics 2003; 34(2): 117-119. 
21 Rabino, op. cit. note 17. 
22 I. Rabino. The Impact of Activist Pressures on Recombinant DNA Research. Science Technology 
and Human Values 1991; 16(1): 70-87. 
23 Ibid. 
24 Rabino, op. cit. note 15. 
25 H. Middleton-Price. 1997. The Role of Genetics Professionals in Public Debate – Summary of 
Survey Results. Available at: 
http://www.bshg.org.uk/documents/other_docs/BSHG%20survey%20results%20HMP.doc. 
26 Matthews et al, op. cit. note 19. 
27 Y. Boisvert, J. Monzée and M.-F. Gagnier. 2004. Bio-Ingénierie, Éthique Et Société: De La 
Responsabilité À La Responsabilisation Des Chercheurs Et Des Entreprises Privées, Laboratoire 
D'éthique Publique Enap: Chaire Fernand-Dumont (Inrs). Montréal: 197. 
28 B. Nicholas. Molecular Geneticists and Moral Responsibility: "Maybe If We Were Working on the 
Atom Bomb I Would Have a Different Argument.” Science and Engineering Ethics 1999; 5(4): 515-
530. 
29 D. Nelkin. Promotional Metaphors and Their Popular Appeal Public Understanding of Science 1994; 
3(1): 25-31. 
30 A. Kerr, S. Cunningham-Burley and A. Amos. Eugenics and the New Genetics in Britain: Examining 
Contemporary Professionals' Accounts. Science, Technology and Human Values 1998; 23(2): 175-198. 
31 A. Kerr, S. Cunningham-Burley and A. Amos. The New Genetics: Professionals' Discursive 
Boundaries. The Sociological Review 1997; 45(2): 279-303. 
32 Nelkin, op. cit. note 29 
33 Nelkin, op. cit. note 6. 
34 R. Dalpé, L. Bouchard and D. Ducharme. Scientific, Medical and Industrial Issues in Breast and 
Ovarian Cancer Genes Research. IEEE International Symposium on Technology and Society, 2000: 
91-99. 
35 I. Rabino. Societal and Commercial Issues Affecting the Future of Biotechnology in the United 
States: A Survey of Researchers' Perceptions. Naturwissenschaften 1998; 85(3): 109-116. 
36 E.G. Campbell, B.R. Clarridge, M. Gokhale, L. Birenbaum, S. Hilgartner, N.A. Holtzman and D. 
Blumenthal. Data Withholding in Academic Genetics: Evidence from a National Survey. JAMA 2002; 
287(4): 473-480. 
37 Blumenthal et al, op. cit. notes 4 & 5. 
38 D.L. Kleinman. Untangling Context: Understanding a University Laboratory in the Commercial 
World. Science, Technology, and Human Values 1998; 3(3): 285-314. 
39 H.A. ten Have and A. Lelie. Medical Ethics Research between Theory and Practice. Theor. Med. 
Bioeth. 1998; 19(3): 263-276. 
40 A. Molewijk, A.M. Stiggelbout, W. Otten, H.M. Dupuis and J. Kievit. Implicit Normativity in 
Evidence-Based Medicine: A Plea for Integrated Empirical Ethics Research. Health Care Analysis 
2003; 11(1): 69-92. 
41 L.v.d. Scheer and G. Widdershoven. Integrated Empirical Ethics: Loss of Normativity? Medicine, 
health care and philosophy 2004; 7(1): 71-79. 
42 P. Ricœur. 1990. Le Soi Et La Visée Éthique. In Soi-Même Comme Un Autre. P. Ricœur. Paris. 
Éditions du Seuil: 199-236. 
43 P. Ricœur. 1990. Le Soi Et L'identité Narrative. In Soi-Même Comme Un Autre. P. Ricœur. Paris. 
Éditions du Seuil: 167-198. 
44 H. Blumer. What Is Wrong with Social Theory? American Sociological Review 1954; 19(1): 7. 
45 D. Fisher and J. Atkinson-Grosjean. Brokers on the Boundary: Academy-Industry Liaison in 
Canadian Universities. Higher Education 2002; 44: 449–467. 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2006, Vol.2, No.3, pp.96-114 
 
_____________  113 
 
Genomics, Society and Policy, Vol.2 No.3 (2006) ISSN: 1746-5354 
                                                                                                                                            
46 H. Etzkowitz. Research Groups as ‘Quasi-Firms’: The Invention of the Entrepreneurial University. 
Research Policy 2003; 32: 109–121. 
47 Schafer, op. cit. note 3. 
48 J. Tuunainen. Hybrid Practices? Contributions to the Debate on the Mutation of Science and 
University. Higher Education 2005; 50(2): 275-298. 
49 M. Gibbons, C. Limoges, H. Nowotny, S. Schwartzman, P. Scott and M. Trow. 1994. The New 
Production of Knowledge: The Dynamics of Science and Research in Contemporary Societies. 
Londres. Sage. 
50 M. Gibbons. 2003. Globalisation and the Preservation of University Values. Available at 
www.bth.se/exr/hss03.nsf/(WebFiles)/E5366FF501835566C1256D4300338EB4/ 
51 H. Etzkowitz and L. Leydesdorff. The Dynamics of Innovation: From National Systems and ‘‘Mode 
2’’ to a Triple Helix of University–Industry–Government Relations. Research Policy 2000; 29: 109-
123. 
52 H. Etzkowitz, A. Webster, C. Gebhardt and B.R.C. Terra. The Future of the University and the 
University of the Future: Evolution of Ivory Tower to Entrepreneurial Paradigm. Research Policy 2000; 
29: 313–330. 
53 Etzkowitz and Leydesdorff, op. cit. note 51. 
54 R. Viale and H. Etzkowitz. 2005. Third Academic Revolution: Polyvalent Knowledge; The "DNA" 
Of the Triple Helix. Turin, Italie. 
55 Etzkowitz et al, op. cit. note 52. 
56 Viale and Etzkowitz, op. cit. note 54. 
57 S. Slaughter and L.L. Leslie. 1997. Academic Capitalism: Politics, Policies, and the Entrepreneurial 
University. Baltimore. The Johns Hopkins University Press: 276. 
58 S. Slaughter and L.L. Leslie. Expanding and Elaborating the Concept of Academic Capitalism. 
Organization overviews 2001; 8(2): 154–161. 
59 M.A. Dennis. Accounting for Research: New Histories of Corporate Laboratories and the Social 
History of American Science. Social studies of science 1987; 17(3): 510. 
60 B. Godin. Writing Performative History: The "New" New Atlantis? Social studies of science 1998; 
23(3): 465-483. 
61 Tuunainen, op. cit. note 48; Etzkowitz and Leydesdorff, op. cit. note 51. 
62 Etzkowitz, op. cit. note 46. 
63 Ibid; Fisher and Atkinson-Grosjean, op. cit. note 45; Tuunainen, op. cit. note 48. 
64 D.B. Resnik and A.E. Shamoo. Conflict of Interest and the University. Accountability in Research 
2002; 9(1): 45-64. 
65 Tuunainen, op. cit. note 48; Slaughter and Leslie, op. cit. note 57. 
66 Slaughter and Leslie, op. cit. note 57. 
67 Tuunainen, op. cit. note 48. 
68 Etzkowitz and Leydesdorff, op. cit. note 51. 
69 Resnik and Shamoo, op. cit. note 64. 
70 Fisher and Atkinson-Grosjean, op. cit. note 45. 
71 US/Governement. 1980. Bayh-Dole Act - Patent and Trademark Law Amendment Act. 
72 Resnik and Shamoo, op. cit. note 64. 
73 Etzkowitz and Leydesdorff, op. cit. note 51. 
74 J. Poyago-Theotoky, J. Beath and D.S. Siegel. Universities and Fundamental Research: Reflections 
on the Growth of University-Industry Partnerships. Oxford Review of Economic Policy 2002; 18(1): 
10-21. 
75 D. Rahm. Academic Perceptions of University-Firm Technology Transfer. Policy Studies Journal 
1994; 22(2): 267-278. 
76 S. Bagchi-Sen, L. Hall and L. Petryshyn. A Study of University-Industry Linkages in the 
Biotechnology Industry: Perspectives from Canada. International Journal of Biotechnology 2001; 3(3-
4): 390-410. 
77 Blumenthal et al, op. cit. notes 4 & 5. 
78 Ibid; Tuunainen, op. cit. note 48; Gibbons et al, op. cit. note 49; Slaughter and Leslie, op. cit. note 
57. 
79 J.A. Lee. What Was Genomics? Lancet Oncology 2003; 4(9): 584. 
80 J. Calvert. The Idea Of "Basic Research" In Language and Practice. Minerva 2004; 42: 251-268. 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2006, Vol.2, No.3, pp.96-114 
 
_____________  114 
 
Genomics, Society and Policy, Vol.2 No.3 (2006) ISSN: 1746-5354 
                                                                                                                                            
81 J. Calvert. What's Special About Basic Research? Science, Technology and Human Values 2006; 
31(2): 199-220. 
82 Viale and Etzkowitz, op. cit. note 54. 
83 Schafer, op. cit. note 3. 
84 J. Thomson, P. Baird and J. Downie. 2001. Report of the Committee of Inquiry on the Case 
Involving Dr. Nancy Olivieri, the Hospital for Sick Children, the University of Toronto, and Apotex 
Inc. - the Summary. Ottawa. Association canadienne des professeures et professeurs d'université: 46. 
85 D. Blumenthal, N. Causino, E.G. Campbell and K.S. Louis. Relationships between Academic 
Institutions and Industry in the Life Sciences - an Industry Survey. New England Journal of Medicine 
1996; 334(6): 368-373. 
86 B. Rappert and A. Webster. Regimes of Ordering: The Commercialization of Interllectual Property in 
Industrial-Academic Collaborations. Technology Analysis and Strategy Managment 1997; 9(2): 115-
130. 
87 S. Lewis, P. Baird, R.G. Evans, W.A. Ghali, C.J. Wright, E. Gibson and F. Baylis. Dancing with the 
Porcupine: Rules for Governing the University–Industry Relationship. Canadian medical association 
journal 2001; 165(6): 783-785. 
88 Fisher and Atkinson-Grosjean, op. cit. note 45. 
89 Schafer, op. cit. note 3; Resnik and Shamoo, op. cit. note 6; S.M. Natale and A.F. Libertella. 
Education-Business Partnership: Shifting Sands in the University and Corporate Community. The 
Journal of Value Inquiry 1998; 32: 257–268. 
90 Natale and Libertella, op. cit. note 89. 
91 B. Williams-Jones. Knowledge Commons or Economic Engine - What's a University For? Journal of 
Medical Ethics 2005; 31(5): 249-250. 
92 Resnik and Shamoo, op. cit. note 64; Natale and Libertella, op. cit. note 89. 
93 D. B. Resnik. Conflicts of Interest in Science. Perspectives on Science 1998; 381-408; Etzkowitz, op. 
cit. note 45; Resnik and Shamoo, op. cit. note 64. 
94 Ezkowitz, op. cit. note 46; Resnik and Shamoo, op. cit. note 64; Resnik, op. cit. note 93. 
95 Lewis et al, op. cit. 87. 
96 Ibid. 
97 Etzkowitz and Leydesdorff, op. cit. note 51. 
© ESRC Genomics Network.
